Based on the results of a phase Ib/II PANACEA trial, pembrolizumab and trastuzumab exhibited response in HER2-positve breast cancer.
Based on the results of a cervical cancer cohort in KEYNOTE-028 trial, pembrolizumab showed durable antitumor activity in advanced cervical cancer.
CancerNetwork ; Publication
It was found that breast or ovarian tumors with LOH at BRCA1/2 is associated with sensitivity to drug response. Locus-specific LOH can be a kind of biomarker to evaluate the effectiveness of DNA damaging drugs in patients with germline BRCA1/2 mutation.
The U.S. Food and Drug Administration (FDA) approved Memorial Sloan Kettering Cancer Center’s (MSKCC) tumor profiling test as an in vitro diagnostics (IVD).
An updated phase I clinical trial data revealed the efficiency of larotrectinib in pediatric cancer with TRK fusion.
Based on the results of a single-arm, phase 2 SARC028 study, pembrolizumab exhibited response in two subtypes of advanced sarcoma: undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Publication : Lancet Oncol. 2017 Oct 4. pii: S1470-2045(17)30624-1. doi: 10.1016/S1470-2045(17)30624-1.
At the International Association for the Study of Lung Cancer (IASLC) Annual Conference in Japan this year, a research shows that liquid biopsy is able to detect unknown driver mutations in advanced non-small cell lung cancer (NSCLC) using next-generation
Cancer Therapy Advisor
The results of the clinical trial on treating ROS1 fusion-positive patients of advanced non-small cell lung cancer with entrectinib were presented at the 18th World Conference on Lung Cancer (WCLC). Entrectinib showed clinical benefits and tolerable adver
A preliminary analysis of a phase II clinical trial data of poziotinib that treats non-small cell lung cancer patients with EGFR exon 20 insertion was presented at the 18th World Conference on Lung Cancer (WCLC). Poziotinib was confirmed to have significa
Following cancer genetic testing guideline to screen target patients and gene list may miss some heritable gene mutations. MSKCC cancer center suggests using broad cancer-related gene panels, which provides more comprehensive information to evaluate the g